BRIDGEWATER, N.J., March 03, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, and ...
BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $31.1 million in its fourth quarter. The Bridgewater, New Jersey-based ...
BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), a biopharmaceutical company with a market capitalization of $2.4 billion and "GREAT" financial health according to InvestingPro ...
Reports Q4 revenue $731M, consensus $708.07M. “Amneal’s continued success in 2024 demonstrates our ability to drive sustainable growth through disciplined execution, continuous innovation ...
Barclays raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $11 from $10 and keeps an Overweight rating on the shares. The company’s Q4 beat, “strong” 2025 guidance and ...
If you want to know who really controls Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), then you'll have to look at the makeup of its share registry. We can see that individual insiders own the lion's ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and ...
JP Morgan upgraded Amneal to Overweight, raising its price target to $12, citing strong generics growth and expanding biosimilar adoption. Every week, our Whisper Index uncovers five overlooked ...
Amneal reported Q4 sales of $730.52M, up 18% Y/Y, beating estimates, while adjusted EPS of $0.12 missed the $0.15 consensus. 2025 guidance: Revenue of $3B-$3.1B, adjusted EPS of $0.65-$0.70, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback